Andrea Lampis
Overview
Explore the profile of Andrea Lampis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
2198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghidini M, Hahne J, Hahne J, Senti C, Heide T, Proszek P, et al.
Clin Cancer Res
. 2024 Dec;
31(4):707-718.
PMID: 39688961
Purpose: We tested whether circulating tumor DNA (ctDNA) changes may be used to assess early response and clinical outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line systemic anticancer...
2.
Fernandez-Mateos J, Cresswell G, Trahearn N, Webb K, Sakr C, Lampis A, et al.
Nat Cancer
. 2024 Jul;
5(9):1334-1351.
PMID: 38997466
Cancer evolution lays the groundwork for predictive oncology. Testing evolutionary metrics requires quantitative measurements in controlled clinical trials. We mapped genomic intratumor heterogeneity in locally advanced prostate cancer using 642...
3.
Hedayat S, Cascione L, Cunningham D, Schirripa M, Lampis A, Hahne J, et al.
Clin Cancer Res
. 2024 Feb;
30(10):2140-2159.
PMID: 38376926
Purpose: The multi-kinase inhibitor (mKi) regorafenib has demonstrated efficacy in chemorefractory patients with metastatic colorectal cancer (mCRC). However, lack of predictive biomarkers and concerns over significant toxicities hamper the use...
4.
Lote H, Mousoullou F, Vlachogiannis G, Lampis A, Satchwell L, Peckitt C, et al.
Front Oncol
. 2023 Dec;
13:1258365.
PMID: 38094609
Background: This study aimed to identify microRNAs (miRs) as circulating biomarkers of resistance to first-line trastuzumab-based therapy in advanced HER2-positive oesophago-gastric cancer patients. Methods: A high-throughput 1015 Exiqon miRCURY LNA™...
5.
Carotenuto P, Amato F, Lampis A, Rae C, Hedayat S, Previdi M, et al.
Nat Commun
. 2021 Nov;
12(1):6738.
PMID: 34795259
FOLFIRINOX, a combination of chemotherapy drugs (Fluorouracil, Oxaliplatin, Irinotecan -FOI), provides the best clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients. In this study we explore the role of miRNAs...
6.
Ratti M, Grizzi G, Passalacqua R, Lampis A, Cereatti F, Grassia R, et al.
Expert Opin Ther Targets
. 2021 Sep;
25(8):677-683.
PMID: 34488530
Introduction: Despite the efforts of the scientific community, the prognosis of metastatic colorectal cancer (mCRC) remains poor. Actionable gene fusions such as Neurotrophic Tropomyosin Receptor Kinases rearrangements are rare but...
7.
Lampis A, Hahne J, Gasparini P, Cascione L, Hedayat S, Vlachogiannis G, et al.
Cell Death Differ
. 2021 Jul;
28(10):2970-2982.
PMID: 34226680
Junctional adhesion molecules (JAMs) play a critical role in cell permeability, polarity and migration. JAM-A, a key protein of the JAM family, is altered in a number of conditions including...
8.
Lampis A, Ratti M, Ghidini M, Mirchev M, Okuducu A, Valeri N, et al.
Int J Mol Med
. 2021 Apr;
47(6).
PMID: 33846775
Oesophageal cancer is one of the most aggressive malignancies with limited treatment options, thus resulting in a high morbidity and mortality. With 5‑year survival rates of only 5‑10%, oesophageal cancer...
9.
Ghidini M, Lampis A, Mirchev M, Okuducu A, Ratti M, Valeri N, et al.
Genes (Basel)
. 2021 Jan;
12(1).
PMID: 33383713
Pancreatic cancer is one of the most aggressive malignancies with limited treatment options thus resulting in high morbidity and mortality. Among all cancers, with a five-year survival rates of only...
10.
Smyth E, Vlachogiannis G, Hedayat S, Harbery A, Hulkki-Wilson S, Salati M, et al.
Gut
. 2020 Nov;
70(9):1632-1641.
PMID: 33199443
Objective: Epidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients. Here, we tested the association between outcome and copy number (CN)...